What is the cardiovascular disease risk category for a 55-year-old male with clinic blood pressure 140/90 mmHg, home blood pressure ≤130/85 mmHg, no known chronic disease, not on any medications, normal renal function, normal complete blood count, and HbA1c 4.4%, but without lipid profile or smoking status information?

D. Risk cannot be identified

The cardiovascular disease risk for this patient cannot be accurately determined because critical information required for formal risk stratification is missing—specifically, lipid profile and smoking status.

Why Risk Assessment is Incomplete

According to the most recent 2024 ESC guidelines 1, cardiovascular risk assessment follows a structured 4-step approach:

1. First, identify high-risk conditions (established CVD, chronic kidney disease, diabetes, familial hypercholesterolemia, or hypertension-mediated organ damage)
2. If absent, calculate 10-year CVD risk using SCORE2 or SCORE2-OP
3. Consider risk modifiers if borderline risk (5%-<10%)
4. Use additional risk tools if uncertainty remains

This patient does not have established high-risk conditions (no CVD, normal kidney function, HbA1c 4.4% rules out diabetes). However, formal risk calculation using SCORE2 or the ACC/AHA Pooled Cohort Equations requires lipid values (total cholesterol, LDL-C, HDL-C) and smoking status—both of which are absent 1, 2, 3.

The White Coat Hypertension Consideration

The discrepancy between clinic BP (140/90 mmHg) and home BP (≤130/85 mmHg) suggests white coat hypertension. Research demonstrates that home BP more accurately predicts cardiovascular outcomes than clinic BP 4, 5. A meta-analysis showed that elevated home BP significantly predicts cardiovascular events even when clinic BP appears normal 4.

Using the 2024 ESC thresholds 1:

• Clinic BP 140/90 mmHg = Grade 1 hypertension
• Home BP ≤130/85 mmHg = High-normal or elevated BP (depending on exact values)

The 2020 ISH guidelines 6 define hypertension as office BP ≥140/90 mmHg confirmed by home BP ≥135/85 mmHg or 24-hour ambulatory BP ≥130/80 mmHg. This patient's home readings suggest he may not meet hypertension criteria, though ambulatory monitoring would provide definitive confirmation.

What Information is Actually Available

From the 2007 ESC/ESH risk stratification framework 7, we can identify:

• Age 55 years (male) = 1 risk factor
• Blood pressure status = uncertain (white coat vs. true hypertension)
• No diabetes (HbA1c 4.4%)
• No target organ damage (normal kidney function)
• Unknown: smoking status, lipid profile, family history, abdominal obesity

Clinical Pitfalls to Avoid

1. Do not assume low risk based solely on normal HbA1c and kidney function—dyslipidemia is a major independent risk factor that remains unmeasured 8, 9

2. Do not treat based on clinic BP alone without confirming with home or ambulatory monitoring, as this leads to overestimation of CVD risk and unnecessary treatment 5

3. Do not proceed with treatment decisions until obtaining lipid profile and smoking history—the 2024 ESC guidelines explicitly require SCORE2 calculation (which needs lipids) before initiating pharmacotherapy for BP 130-139/80-89 mmHg 1

Next Steps Required

Before risk stratification can be completed:

• Obtain fasting lipid profile (total cholesterol, LDL-C, HDL-C, triglycerides)
• Document smoking status
• Confirm BP status with 24-hour ambulatory monitoring or structured home BP monitoring over 3-7 days
• Screen for other risk factors: family history of premature CVD, waist circumference

Only after obtaining these essential data points can formal risk calculation using SCORE2 1 or Pooled Cohort Equations 2, 3 be performed to categorize this patient as low (<5%), borderline (5%-<7.5%), intermediate (7.5%-<20%), or high (≥20%) 10-year CVD risk.